- A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
- A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
- A Phase 1/2 Study of SC-43 in Combination With Cisplatin
- A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
- A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
- A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
- A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
- A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis
- A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors
- A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
- A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer
- A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
- A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
- A Study of ABL001 in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
- A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
- A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
- A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
- A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer.
- A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
- A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
- A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients
- A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
- A Trial of SHR1258 in Patients With Biliary Tract Cancer
- Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
- Allogeneic NK Cell (“SMT-NK”) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
- Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
- An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
- Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
- Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
- Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers
- AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)
- Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
- Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Unresectable Biliary Tract Cancer.
- Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC.
- Case Series Study of Biliary Tract Cancer Patients in Japan
- Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
- Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
- Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures.
- Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）
- ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial.
- Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer
- Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
- Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
- Early Palliative Care on Quality of Life of Advanced Cancer Patients
- Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
- Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis
- Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
- Extracellular RNA Markers of Liver Disease and Cancer
- FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
- FOLFIRINOX for 2nd-line Treatment of BTC
- GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer
- GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer
- Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
- Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer
- Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer
- GTX Regimen for Biliary Cancers
- IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
- Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
- IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
- Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
- Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
- Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer
- Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
- MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
- Metabolic Stress-induced Exercise to Prevent Loss of Muscle Mass in Patients With Pancreatic and Biliary Tract Cancer
- Molecular Profiling of Advanced Biliary Tract Cancers
- Molecular Profiling of Advanced Biliary Tract Cancers
- Multibending vs Conventional Endoscope for Direct Peroral Cholangioscopy
- My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
- NGS as the First-line Treatment in Advanced Biliary Tract Cancer
- Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
- Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer
- Palliadelic Treatment to Reduce Psychological Distress in Persons With Inoperable Pancreatobiliary Cancer
- Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions
- Patient Activation Through Counseling, Exercise and Mobilization
- Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
- Perception Prognosis, Goals of Treatment, and Communication
- Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
- Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
- Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
- Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
- Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer
- Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
- Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
- Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
- Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
- Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
- Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
- Predicting Disease Progression and/or Recurrence in Cancer
- Preoperative Nutritional Support in Malnutritional Cancer Patients
- Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study
- PT-112 (Phosplatin’s Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors
- Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
- Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
- RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2
- Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
- Second Line Therapy in Advanced Biliary Tract Cancer
- SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
- Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
- Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
- Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
- Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy
- Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
- Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
- Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)
- Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
- Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
- Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
- Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
- Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control
- Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery
- The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma
- The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies
- The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
- The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer
- Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
- Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer
- Trastuzumab in HER2-positive Biliary Tract Cancer
- Tremelimumab With Chemoembolization or Ablation for Liver Cancer
- Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers
- Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
- Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
- Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
- Vessel Resection and Reconstruction of Biliary Tract Cancers
- X-MAS Biliary Study With Covered Biliary Stent
- XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy
- XmAb20717 in Advanced Biliary Tract Cancers
Clinical Trials
- A Randomized Phase III Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- A Study of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia
- A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
- A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
- A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat
- Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
- Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
- Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
- Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
- First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia
- Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
- Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
- Management of Mixed-Phenotype Acute Leukemia in the East of France
- Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
- Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
- Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
- Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
- Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
- Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population.
- CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
- Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)
- Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies
- DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia
- PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
- Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
- Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies
- Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
- Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS.
- A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
- Amphotericin-B and Voriconazole for Pulmonary Blastomycosis
- Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection
- A Mechanical Device for Blepharospasm
- A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm
- A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
- An RCT of a Patient-initiated Treatment Service for BEB and HFS
- Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
- Blepharospasm Patient Survey for Patients With Blepharospasm
- Blepharospasm Short Interval
- Blepharospasm Tools
- Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm
- Brain Changes in Blepharospasm
- Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm
- Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
- Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
- Data Analysis of Protocol 04-N-0188: Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives
- Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
- Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
- Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
- IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
- Mexiletine for the Treatment of Focal Dystonia
- Photic Blink Reflex in People With Blepharospasm and Increased Blinking
- Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
- Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
- Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
- Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm
- Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
- Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
- Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
- Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
- Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
- Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
- Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
- Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
- Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
- The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.
- The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population
- TPO Use in Children for Hemotopoietic Failure
- Treo for BMFD Post HCT
- Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
- Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
- Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
- A Prospective Study: Artificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface
- A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.
- A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
- A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
- A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer
- An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry
- Bonefos and the Consumption of Analgesics
- Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute
- Cross Cultural Validation of the Italian Version of the Bt-DUX
- Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
- FREE Study – Fracture Reduction Evaluation
- Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases
- Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study
- Multicentric Bone Tumor Imaging Report and Data System
- Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II
- Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
- Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery
- Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
- Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions
- Capturing Parkinson’s Disease Medication Side Effects During Daily Activities
- Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia
- Movement Disorders Analysis Using a Deep Learning Approach
- Pilot Study for Automated Deep Brain Stimulation Programming
- Rhythmic Auditory Stimulation on Upper-limb Movements in PD Patients
- Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson’s Disease Patients
- A Study of Cognitive Changes in Patients Receiving Brain Radiation
- Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
- Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
- Comparing Immobilisation Shells in Cranial Radiotherapy
- Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors
- Effects of Intravenous Anesthesia and Balanced Anesthesia on Flash Visual Evoked Potentials
- FBY PET/CT in Patients With Brain Tumors
- Handheld Dynamometer During Awake Craniotomy Pilot
- Induction of Cortical Plasticity
- Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors
- Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy
- Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy
- Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma
- Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
- Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
- Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma
- Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
- Prevalence of Post-craniotomy Headache in Siriraj Hospital
- Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma
- S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
- Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas
- Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
- Wise Cortical Strip for Intraoperative Neurophysiological Monitoring